In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

Excellence in business comes in many forms. For some companies, it’s a creative use of artificial intelligence to drive growth. For others, it’s a viral marketing campaign or a game-changing invention ...

Become a Scroll member to get Rush Hour – a wrap of the day’s important stories delivered straight to your inbox every evening.

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.